QURIENT CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,200 KRW | -0.83% |
|
+2.94% | -10.06% |
| Sales 2022 | 8.47K 11.62M | Sales 2023 | 9.03K 12.39M | Capitalization | 90.36B 123,991B |
|---|---|---|---|---|---|
| Net income 2022 | -25.46B -34,933B | Net income 2023 | -21.12B -28,978B | EV / Sales 2022 | 10,369,450 x |
| Net cash position 2022 | 32.29B 44,311B | Net cash position 2023 | 42.49B 58,303B | EV / Sales 2023 | 5,300,023 x |
| P/E ratio 2022 |
-5.02
x | P/E ratio 2023 |
-3.91
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.26% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.83% | ||
| 1 week | +2.94% | ||
| Current month | -0.83% | ||
| 1 month | -3.67% | ||
| 3 months | -3.11% | ||
| 6 months | +25.95% | ||
| Current year | -10.06% |
1 week
3 960.00
4 280.00
1 month
3 900.004 710.00
Current year
3 450.005 030.00
1 year
2 361.548 715.38
3 years
2 361.5415 076.92
5 years
2 361.5432 653.85
10 years
2 361.5446 384.62
| Managers | Title | Age | Since |
|---|---|---|---|
Ki-Yean Nam
CEO | Chief Executive Officer | 53 | 08-07-01 |
Peter Yu
DFI | Director of Finance/CFO | 51 | 22-07-31 |
Gi-Won Choi
COO | Chief Operating Officer | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ki-Yean Nam
CEO | Chief Executive Officer | 53 | 08-07-01 |
Jae-Seung Kim
BRD | Director/Board Member | 56 | - |
Gi-Won Choi
COO | Chief Operating Officer | 52 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-02 | 4,200 | -0.83% | 52 888 |
| 24-05-31 | 4,235 | +4.57% | 79,736 |
| 24-05-30 | 4,050 | -0.37% | 62,934 |
| 24-05-29 | 4,065 | -1.57% | 84,654 |
| 24-05-28 | 4,130 | +0.49% | 60,702 |
End-of-day quote Korea S.E., June 02, 2024
More quotes
Qurient Co., Ltd. is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -10.06% | 93.21M | |
| +23.34% | 74.04B | |
| -1.84% | 24.18B | |
| +3.42% | 8.46B | |
| +9.92% | 8.34B | |
| -23.66% | 7.64B | |
| +13.06% | 5.33B | |
| +2.27% | 4.12B | |
| -6.90% | 3.92B | |
| +3.99% | 3.89B |
- Stock Market
- Equities
- A115180 Stock
